Accepting Immunotherapy After Multiline Treatment Failure: An Exploration of the Anxiety and Depression in Patients with Advanced Cancer Experience

被引:7
作者
Xie, Qingqing [1 ]
Sun, Caixia [2 ]
Fei, Zhenghua [1 ]
Yang, Xujing [1 ]
机构
[1] Wenzhou Med Univ, Dept Radiat & Med Oncol, Affiliated Hosp 1, 2 Fuxue Lane, Wenzhou 325000, Peoples R China
[2] Wenzhou Med Univ, Dept Nursing, Affiliated Hosp 1, Wenzhou 325000, Peoples R China
关键词
anxiety; depression; cancer; immunotherapy; quality of life; HOSPITAL ANXIETY; SCALE; NIVOLUMAB; ANTIBODY;
D O I
10.2147/PPA.S346171
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Tumor immunotherapy is a promising therapeutic strategy for patients with advanced cancers, and some tumors have profound and durable tumor regression. However, immunotherapy is still in the clinical trial stage with elusive long-term effects and complications as a new strategy. It is unclear whether patients possess an accurate understanding of the clinical benefits associated with these agents. Objective: To investigate the anxiety and depression of patients with advanced cancer who received immunotherapy using programmed death-1 or programmed death-ligand 1 after multiline treatment failure, explore the influencing factors, and provide a reference for clinical medical staff and psychological support for patients. Methods: The Hospital Anxiety and Depression Scale was used to calculate the anxiety and depression scores before and after 1, 2, and 3 courses of treatment, respectively. The patients with anxiety and depression were counted. Purposive sampling was used to conduct face-toface semi-structured interviews with 21 patients to find out the reasons. The obtained data were analyzed and collated using Colaizzi's phenomenological method. Results: One hundred and twenty-six patients with advanced cancers were included in the study. Before and after 1, 2 and 3 courses of treatment, 18.26%, 23.0%, 50% and 54% of patients suffered from anxiety and depression, respectively. The proportion of patients with anxiety and depression during immunotherapy kept increasing, mainly due to therapeutic efficacy below expectation, lack of timely information after treatment, lack of awareness of treatment and drugs, and lack of family and social support. Conclusion: Patients with advanced tumors after multiline treatment failure are susceptible to anxiety and depression during immunotherapy. It is necessary to test the emotional state of patients in time and carry out early intervention. Nursing staffs and medical staffs should adopt personalized measures to meet the psychological needs of patients.
引用
收藏
页码:1 / 9
页数:9
相关论文
共 26 条
[21]   Factor analysis of the Hospital Anxiety and Depression Scale from a large cancer population [J].
Smith, AB ;
Selby, PJ ;
Velikova, G ;
Stark, D ;
Wright, EP ;
Gould, A ;
Cull, A .
PSYCHOLOGY AND PSYCHOTHERAPY-THEORY RESEARCH AND PRACTICE, 2002, 75 :165-176
[22]  
Thomas BC, 2005, INDIAN J MED RES, V122, P395
[23]   Analysis of Intra-Tumoral Macrophages and T Cells in Non-Small Cell Lung Cancer (NSCLC) Indicates a Role for Immune Checkpoint and CD200-CD200R Interactions [J].
Tondell, Anders ;
Subbannayya, Yashwanth ;
Wahl, Sissel Gyrid Freim ;
Flatberg, Arnar ;
Sorhaug, Sveinung ;
Borset, Magne ;
Haug, Markus .
CANCERS, 2021, 13 (08)
[24]  
Trevino Kelly M, 2012, J Support Oncol, V10, P124, DOI 10.1016/j.suponc.2011.08.005
[25]  
[杨坡 Yang Po], 2016, [中国肿瘤临床, Chinese Journal of Clinical Oncology], V43, P452
[26]  
Zheng R S, 2019, Zhonghua Zhong Liu Za Zhi, V41, P19, DOI 10.3760/cma.j.issn.0253-3766.2019.01.005